Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Business Wire
ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well toleratedARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026Cash runway extended into Q2 2028Investor conference call at 4:30 p.m. ET today SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates.“Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12-week cystic fibrosis (CF) study in the first half of 2026,” said Joseph Payne, President & CEO of Arcturus. “We remain firmly committed to advancing our once-daily inha
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics (ARCT) had its price target lowered by Citigroup Inc. from $66.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- Arcturus Therapeutics to Attend Upcoming Investor ConferenceBusiness Wire
- Arcturus Therapeutics (ARCT) had its price target raised by Citigroup Inc. from $7.00 to $8.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcturus Therapeutics (ARCT) had its price target lowered by Piper Sandler from $72.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 3/3/26 - Miss
ARCT
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- ARCT's page on the SEC website